VEGFA and wet macular degeneration: Thus, targeting VEGF is an efficient strategy for treating wet AMD.27, 28 Currently, several neutralizing antibodies targeting VEGF, including bevacizumab, ranibizumab and aflibercept, are used for treating neovascular AMD and show good therapeutic effect clinically.29, 30, 31 Dual functional neutralizing antibody IBI302 targeting VEGF and complement system also showed promise as a candidate for AMD treatment.32 In our study, results demonstrated the protective role of SARI in laser‐induced CNV model in mice, evidenced by less leakage and severity of CNV in SARIWT mice.